6.3.3. treatment high-risk localised disease. patients high-risk pca increased risk psa failure, need secondary therapy, metastatic progression death pca. nevertheless, high-risk pca patients uniformly poor prognosis rp . managed non-curative intent, high-risk pca associated 10-year 15-year pcsm rates 28.8 35.5%, respectively . consensus regarding optimal treatment men high-risk pca. evidence suggests radical treatment high-risk pca delayed three months diagnosis without oncological consequences . systematic reviews suggest higher risk biochemical recurrence worse pathological outcomes definitive treatment given beyond 6 9 months delay. however, conclusive data regarding stronger endpoints (css os). 6.3.3.1. radical prostatectomy provided tumour fixed pelvic wall invasion urethral sphincter, rp standard option selected patients low tumour volume. eplnd provides accurate ln staging. pre-operative psma-pet/ct accurate staging generally, miss smaller lns (especially lns <5mm). eplnd may also miss ln metastasis . risks benefits pelvic ln dissection vs. psma pet/ct discussed patient pre-operatively. patients aware pre-operatively surgery may part multi-modal treatment, adjuvant srt adt. neoadjuvant therapy using adt without new generation ht docetaxel indicated. (see section 6.1.2.2.4) . nerve sparing management discussed section 6.1.2.3.5. 15 years follow-up cn0 patients undergo rp found pn1 reported overall css os 45% 42%, respectively . sr reported 10-year bcr-free, css, os rates ranging 28% 56%, 72% 98%, 60% 87.6%, respectively, pn1 patients . findings highlight pn1 patients represent heterogeneous patient group treatment must individualised based risk factors (see sections 6.2.5.2 6.2.5.6). 6.3.3.2. external beam radiation therapy high-risk localised pca, combined modality approach used consisting imrt/vmat plus long-term adt. duration adt take account ps, comorbidities number poor prognostic factors. important recognise several studies ebrt plus short-term adt improve os high-risk localised pca long-term adt (at least 2 3 years) currently recommended patients . moderate hfx option selected high-risk patients localised disease. chhip study included 12% high-risk patients (n = 386) limited entry psa < 30 ng/ml roach formula risk sv involvement < 30% . patients ineligible t3a tumours isup grade group 4 higher. 6.3.3.2.1. lymph node irradiation cn0 clear evidence prophylactic irradiation pelvic lns intermediate- high-risk disease. long-term results nrg/rtog 9413-trial randomised intermediate-risk high-risk localised pca patients (1,322 cn0 patients enrolled), showed neoadjuvant ht plus whole pelvic rt improved pfs compared neoadjuvant adt plus prostate rt whole pelvic rt plus adjuvant adt . however, increased risk ≥ grade 3 gi-toxicity. well-conducted single-centre rct randomised 224 patients comparing prostate-only rt (port) vs. whole pelvic rt (wprt) localised high-risk- locally-advanced tumours (cn0) risk > 20% positive nodes (roach formula). median follow-up 68 months significant improvement distant mfs (95.9% vs. 89.2%, hr: 0.35, p = 0.01) dfs (89.5% vs.77.2%, p = 0.02). however, significant higher rate late gu ≥ 2 effects (17.7% vs. 7.5%, p = 0.02), trial relatively small size additional limitations findings therefore insufficient define change practice . benefits pelvic nodal irradiation using imrt/vmat merit investigation large scale rcts conducted rtog uk national cancer research institute (ncri). 6.3.3.2.2. brachytherapy boost men nccn unfavourable intermediate- high-risk pca, bt boost supplemental ebrt ht may considered. see sections 6.1.3.4.1 6.1.3.4.2 details rcts comparing ebrt alone ebrt ldr hdr boost, respectively. 6.3.3.3. options surgery radiotherapy primary treatment localised pca currently lack evidence supporting treatment option apart rp radical rt localised high-risk pca. use adt monotherapy addressed eortc 30891 trial (see section 6.2.4.4.2). immediate adt may benefit patients psa-dt < twelve months, either psa > 50 ng/ml poorly-differentiated tumour . 6.3.3.4. guidelines radical palliative treatment high-risk localised disease* recommendationsstrength ratingwatchful waiting (ww)offer ww asymptomatic patients life expectancy < ten years.strongradical prostatectomy (rp)offer rp selected patients part potential multi-modal therapy.weakextended pelvic lymph node dissection (eplnd)in patients undergoing lymph node dissection perform extended plnd.strongdo perform frozen section nodes rp decide whether proceed with, abandon, procedure (see section 6.2.4.1).strongradiotherapeutic treatmentoffer patients intensity-modulated radiation therapy (imrt)/volumetric modu-lated arc therapy (vmat) plus image-guided radiation therapy (igrt) 76–78 gy combination long-term androgen deprivation therapy (adt) (2 3 years).strongoffer focal boosting mri-defined dominant intra-prostatic tumour using normo-fractionated imrt/igrt (1.8-2.0 gy per fraction) ensuring organ risk constraints exceeded.weakoffer patients good urinary function imrt/vmat plus igrt brachy-therapy boost (either high-dose rate low-dose rate), combination long-term adt (2 3 years).weaktherapeutic options outside surgery radiotherapydo offer either whole gland focal therapy.strongonly offer adt monotherapy patients unwilling unable receive form local treatment prostate-specific antigen (psa)-doubling time < twelve months, either psa > 50 ng/ml poorly-differentiated tumour.strong *all recommendations based conventional imaging isotope bone scan ct/mr abdomen/pelvis.